miRNA-382-5p Suppresses the Expression of Farnesoid X Receptor to Promote Progression of Liver Cancer

References

• McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73(Suppl 1):4–13. doi:10.1002/hep.31288
   PubMed Web of Science ®Google Scholar
• Huang Y, Ge W, Zhou J, et al. The role of tumor associated macrophages in hepatocellular carcinoma. J Cancer. 2021;12(5):1284–1294. doi:10.7150/jca.5134633531974
   PubMed Web of Science ®Google Scholar
• Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604. doi:10.1038/s41575-019-0186-y31439937
   PubMed Web of Science ®Google Scholar
• Erstad DJ, Razavi AA, Li S, et al. Prevention strategies for hepatocellular carcinoma. In: Hoshida Y, editor. Hepatocellular Carcinoma: Translational Precision Medicine Approaches. Cham (CH);2019:255–289.
   Google Scholar
• Jung K, Kim M, So J, et al. Farnesoid X receptor activation impairs liver progenitor cell-mediated liver regeneration via the PTEN-PI3K-AKT-mTOR axis in zebrafish. Hepatology. 2020;74(1):397–410.
   Web of Science ®Google Scholar
• Keitel V, Droge CHaussinger D. Targeting FXR in cholestasis. Handb Exp Pharmacol. 2019;256:299–324.31201556
   PubMedGoogle Scholar
• Panzitt K, Wagner M. FXR in liver physiology: multiple faces to regulate liver metabolism. Biochim Biophys Acta Mol Basis Dis. 2021;1867(7):166133. doi:10.1016/j.bbadis.2021.16613333771667
   PubMed Web of Science ®Google Scholar
• Kundu S, Kumar SBajaj S, Bajaj A. Cross-talk between bile acids and gastrointestinal tract for progression and development of cancer and its therapeutic implications. IUBMB Life. 2015;67(7):514–523. doi:10.1002/iub.139926177921
   PubMed Web of Science ®Google Scholar
• Yang F, Huang X, Yi T, et al. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res. 2007;67(3):863–867. doi:10.1158/0008-5472.CAN-06-107817283114
   PubMed Web of Science ®Google Scholar
• Takahashi S, Tanaka N, Fukami T, et al. Role of Farnesoid X receptor and bile acids in hepatic tumor development. Hepatol Commun. 2018;2(12):1567–1582. doi:10.1002/hep4.126330556042
   PubMed Web of Science ®Google Scholar
• Wang YD, Yang F, Chen WD, et al. Farnesoid X receptor protects liver cells from apoptosis induced by serum deprivation in vitro and fasting in vivo. Mol Endocrinol. 2008;22(7):1622–1632. doi:10.1210/me.2007-052718436567
   PubMedGoogle Scholar
• Wang YD, Chen WD, Li C, et al. Farnesoid X receptor antagonizes JNK signaling pathway in liver carcinogenesis by activating SOD3. Mol Endocrinol. 2015;29(2):322–331. doi:10.1210/me.2014-122525496033
   PubMedGoogle Scholar
• Huang XF, Zhao WY, Huang WD. FXR and liver carcinogenesis. Acta Pharmacol Sin. 2015;36(1):37–43. doi:10.1038/aps.2014.11725500874
   PubMed Web of Science ®Google Scholar
• Su H, Ma C, Liu J, et al. Downregulation of nuclear receptor FXR is associated with multiple malignant clinicopathological characteristics in human hepatocellular carcinoma. Am J Physiol Gastrointest Liver Physiol. 2012;303(11):G1245–G1253. doi:10.1152/ajpgi.00439.201123042943
   PubMed Web of Science ®Google Scholar
• Ambros V. microRNAs: tiny regulators with great potential. Cell. 2001;107(7):823–826. doi:10.1016/S0092-8674(01)00616-X11779458
   PubMed Web of Science ®Google Scholar
• Nie X, Liu Y, Chen WD, et al. Interplay of miRNAs and canonical Wnt signaling pathway in hepatocellular carcinoma. Front Pharmacol. 2018;9:657. doi:10.3389/fphar.2018.0065729977206
   PubMed Web of Science ®Google Scholar
• Lu X, Yang C, Hu Y, et al. Upregulation of miR-1254 promotes hepatocellular carcinoma cell proliferation, migration, and invasion via inactivation of the Hippo-YAP signaling pathway by decreasing PAX5. J Cancer. 2021;12(3):771–789.33403035
   PubMed Web of Science ®Google Scholar
• Marin JJ, Bujanda L, Banales JM. MicroRNAs and cholestatic liver diseases. Curr Opin Gastroenterol. 2014;30(3):303–309. doi:10.1097/MOG.000000000000005124553410
   PubMed Web of Science ®Google Scholar
• Krattinger R, Bostrom A, Schioth HB, et al. microRNA-192 suppresses the expression of the farnesoid X receptor. Am J Physiol Gastrointest Liver Physiol. 2016;310(11):G1044–51. doi:10.1152/ajpgi.00297.201527079614
   PubMed Web of Science ®Google Scholar
• Zhang Y, Gong W, Dai S, et al. Downregulation of human farnesoid X receptor by miR-421 promotes proliferation and migration of hepatocellular carcinoma cells. Mol Cancer Res. 2012;10(4):516–522.  doi:10.1158/1541-7786.MCR-11-0473
   Google Scholar
• Bei Y, Song Y, Wang F, et al. miR-382 targeting PTEN-Akt axis promotes liver regeneration. Oncotarget. 2016;7(2):1584–1597. doi:10.18632/oncotarget.644426636539
   PubMedGoogle Scholar
• Zheng Y, Zhou J, Li X, et al. Mir-382 promotes differentiation of rat liver progenitor cell WB-F344 by targeting Ezh2. Cell Physiol Biochem. 2018;48(6):2389–2398. doi:10.1159/00049265430121666
   PubMedGoogle Scholar
• Nie X, Xia F, Liu Y, et al. Downregulation of Wnt3 suppresses colorectal cancer development through inhibiting cell proliferation and migration. Front Pharmacol. 2019;10:1110. doi:10.3389/fphar.2019.0111031632267
   PubMed Web of Science ®Google Scholar
• Liu D, Zhong L, Yuan Z, et al. miR-382-5p modulates the ATRA-induced differentiation of acute promyelocytic leukemia by targeting tumor suppressor PTEN. Cell Signal. 2018;54:1–9. doi:10.1016/j.cellsig.2018.11.01230453015
   PubMed Web of Science ®Google Scholar
• Xu M, Jin H, Xu CX, et al. miR-382 inhibits osteosarcoma metastasis and relapse by targeting Y box-binding protein 1. Mol Ther. 2015;23(1):89–98. doi:10.1038/mt.2014.19725292190
   PubMed Web of Science ®Google Scholar
• Feng J, Qi B, Guo L, et al. miR-382 functions as a tumor suppressor against esophageal squamous cell carcinoma. World J Gastroenterol. 2017;23(23):4243–4251. doi:10.3748/wjg.v23.i23.424328694664
   PubMed Web of Science ®Google Scholar
• Wang Y, Bu P, Li F, et al. [Effects of miR-382 on cell migration, invasion and proliferation of gastric cancer cell lines MGC-803]. Zhonghua Yi Xue Za Zhi. 2017;97(8):612–615. Chinese.28260307
   PubMedGoogle Scholar
• Chen T, Ren H, Thakur A, et al. miR-382 inhibits tumor progression by targeting SETD8 in non-small cell lung cancer. Biomed Pharmacother. 2017;86:248–253. doi:10.1016/j.biopha.2016.12.00728006750
   PubMed Web of Science ®Google Scholar
• Zhang H, Zhu C, He Z, et al. LncRNA PSMB8-AS1 contributes to pancreatic cancer progression via modulating miR-382-3p/STAT1/PD-L1 axis. J Exp Clin Cancer Res. 2020;39(1):179. doi:10.1186/s13046-020-01687-832891166
   PubMed Web of Science ®Google Scholar
• Xie L, Pan Z. Circular RNA circ_0000467 regulates colorectal cancer development via miR-382-5p/EN2 axis. Bioengineered. 2021;12(1):886–897. doi:10.1080/21655979.2021.188913033685351
   PubMed Web of Science ®Google Scholar
• Chen Z, Zheng Z, Feng L, et al. Overexpression of miR-382 sensitizes hepatocellular carcinoma cells to gammadelta T cells by inhibiting the expression of c-FLIP. Mol Ther Oncolytics. 2020;18:467–475. doi:10.1016/j.omto.2020.07.01232953981
   PubMed Web of Science ®Google Scholar
• Li D, Li P, Guo Z, et al. Downregulation of miR-382 by propranolol inhibits the progression of infantile hemangioma via the PTEN-mediated AKT/mTOR pathway. Int J Mol Med. 2017;39(3):757–763. doi:10.3892/ijmm.2017.286328112362
   PubMed Web of Science ®Google Scholar
• Ma Z. Downregulation of SETD8 by miR-382 is involved in glioma progression. Pathol Res Pract. 2018;214(3):356–360. doi:10.1016/j.prp.2018.01.00429487005
   PubMed Web of Science ®Google Scholar
• Ho JY, Hsu RJ, Liu JM, et al. MicroRNA-382-5p aggravates breast cancer progression by regulating the RERG/Ras/ERK signaling axis. Oncotarget. 2017;8(14):22443–22459. doi:10.18632/oncotarget.1233827705918
   PubMedGoogle Scholar
• Wang J, Luo J, Liu G, et al. Circular RNA hsa_circ_0008285 inhibits colorectal cancer cell proliferation and migration via the miR-382-5p/PTEN axis. Biochem Biophys Res Commun. 2020;527(2):503–510. doi:10.1016/j.bbrc.2020.03.16532423803
   PubMed Web of Science ®Google Scholar
• Seok JK, Lee SH, Kim MJ, et al. MicroRNA-382 induced by HIF-1alpha is an angiogenic miR targeting the tumor suppressor phosphatase and tensin homolog. Nucleic Acids Res. 2014;42(12):8062–8072. doi:10.1093/nar/gku51524914051
   PubMed Web of Science ®Google Scholar
• Zhang S, Ge W, Zou G, et al. MiR-382 targets GOLM1 to inhibit metastasis of hepatocellular carcinoma and its down-regulation predicts a poor survival. Am J Cancer Res. 2018;8(1):120–131.29416925
   PubMed Web of Science ®Google Scholar
• Du J, Bai F, Zhao P, et al. Hepatitis B core protein promotes liver cancer metastasis through miR-382-5p/DLC-1 axis. Biochim Biophys Acta Mol Cell Res. 2018;1865(1):1–11. doi:10.1016/j.bbamcr.2017.09.02028982593
   PubMed Web of Science ®Google Scholar
• Maqsood MI, Matin MM, Bahrami AR, et al. Immortality of cell lines: challenges and advantages of establishment. Cell Biol Int. 2013;37(10):1038–1045. doi:10.1002/cbin.1013723723166
   PubMed Web of Science ®Google Scholar
• Zhang Y, Gong W, Dai S, et al. Downregulation of human farnesoid X receptor by miR-421 promotes proliferation and migration of hepatocellular carcinoma cells. Mol Cancer Res. 2012;10(4):516–522. doi:10.1158/1541-7786.MCR-11-047322446874
   PubMed Web of Science ®Google Scholar
• He N, Park K, Zhang Y, et al. Epigenetic inhibition of nuclear receptor small heterodimer partner is associated with and regulates hepatocellular carcinoma growth. Gastroenterology. 2008;134(3):793–802. doi:10.1053/j.gastro.2008.01.00618325392
   PubMed Web of Science ®Google Scholar
• Li G, Kong B, Zhu Y, et al. Small heterodimer partner overexpression partially protects against liver tumor development in farnesoid X receptor knockout mice. Toxicol Appl Pharmacol. 2013;272(2):299–305. doi:10.1016/j.taap.2013.06.01623811326
   PubMed Web of Science ®Google Scholar
• Alvarez-Sola G, Uriarte I, Latasa MU, et al. Fibroblast growth factor 15/19 in Hepatocarcinogenesis. Dig Dis. 2017;35(3):158–165. doi:10.1159/00045090528249259
   PubMed Web of Science ®Google Scholar
• Soroka CJ, Ballatori N, Boyer JL. Organic solute transporter, OSTalpha-OSTbeta: its role in bile acid transport and cholestasis. Semin Liver Dis. 2010;30(2):178–185. doi:10.1055/s-0030-125322620422499
   PubMed Web of Science ®Google Scholar